Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histone deacetylases.

Paul A Marks1, Thomas Miller, Victoria M Richon

  • 1Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. munroed@mskcc.org

Current Opinion in Pharmacology
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spider leg biomechanics as an information filter for vibration sensing.

Proceedings. Biological sciences·2026
Same author

Early Neurodevelopmental Outcomes in Children With Congenital Heart Disease.

JAMA network open·2026
Same author

Multi-site DMS probing reveals higher-order structure of RNA-protein complexes in living cells.

Molecular cell·2026
Same author

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial.

Neonatology·2026
Same author

Correction: Adherence to recommended practices for perioperative anesthesia care for older adults among US anesthesiologists: results from the ASA Committee on Geriatric Anesthesia-Perioperative Brain Health Initiative ASA member survey.

Perioperative medicine (London, England)·2025
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Histone deacetylase inhibitors are a new class of epigenetic drugs that can stop cancer cell growth and cause cancer cell death. Clinical trials show these drugs are well-tolerated and effective against tumors.

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Cancer Research

Background:

  • Post-translational modification of histones regulates gene expression.
  • Histone deacetylases (HDACs) are key epigenetic enzymes.
  • HDAC inhibitors are a class of small molecules targeting these enzymes.

Purpose of the Study:

  • To investigate the role of histone deacetylase inhibitors in cancer.
  • To evaluate the therapeutic potential of HDAC inhibitors in vitro and in vivo.

Main Methods:

  • Utilized small molecules to inhibit histone deacetylase activity.
  • Assessed the effects of HDAC inhibitors on cancer cell lines.
  • Conducted in vitro and in vivo studies to evaluate anti-tumor activity.

Related Experiment Videos

Main Results:

  • HDAC inhibitors induced growth arrest, differentiation, and apoptosis in cancer cells.
  • Clinical trials demonstrated that HDAC inhibitors are well-tolerated.
  • Anti-tumor activity was observed at well-tolerated doses.

Conclusions:

  • Histone deacetylase inhibitors represent a promising therapeutic strategy for cancer treatment.
  • These epigenetic drugs offer a favorable safety profile with demonstrated anti-cancer effects.